CoChat
Sign Up
Cited by 260RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryMicroRNA in disease regulation

Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy

Open access
Devulapally, Rammohan, Sekar, Narayana M., Sekar, Thillai V., Foygel, Kira, Massoud, Tarik F., Willmann, Jürgen K., Paulmurugan, Ramasamy·2015·ACS Nano
DOI 10.1021/nn507465dPMC PMC4374409
Open this paper in CoChat — free account

Abstract

The current study shows the therapeutic outcome achieved in triple negative breast cancer (TNBC) by simultaneously antagonizing miR-21-induced antiapoptosis and miR-10b-induced metastasis, using antisense-miR-21-PS and antisense-miR-10b-PS delivered by polymer nanoparticles (NPs). We synthesized the antisense-miR-21 and antisense-miR-10b loaded PLGA-b-PEG polymer NPs and evaluated their cellular uptake, serum stability, release profile, and the subsequent synchronous blocking of endogenous miR-21 and miR-10b function in TNBC cells in culture, and tumor xenografts in living animals using molecular imaging. Results show that multitarget antagonization of endogenous miRNAs could be an efficient strategy for targeting metastasis and antiapoptosis in the treatment of metastatic cancer. Targeted delivery of antisense-miR-21 and antisense-miR-10b coloaded urokinase plasminogen activator receptor (uPAR) targeted polymer NPs treated mice showed substantial reduction in tumor growth at very low dose of 0.15 mg/kg, compared to the control NPs treated mice and 40% reduction in tumor growth compared to scramble peptide conjugated NPs treated mice, thus demonstrating a potential new therapeutic option for TNBC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/nn507465d

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of miR-21 via different strategies elevated apoptotic cell death, sensitivity to chemotherapy/radiotherapy, and diminished tumor progression.

    “Inhibition of miR-21 via different strategies elevated apoptotic cell death, sensitivity to chemotherapy/radiotherapy, and diminished tumor progression (24–28).”

    From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [24]

    The paper’s Abstract (page unavailable) reports that antisense inhibition of miR-21 induces apoptosis and impairs tumor-cell growth. Its Conclusion (page unavailable) reports reduced tumor growth with combined anti-miR-21/anti-miR-10b nanoparticles. It does not show increased sensitivity to chemotherapy or radiotherapy; the Conclusion proposes combining the approach with chemotherapy as future work. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

  • miR-21 silencing has demonstrated effective results both in vitro and in vivo.

    “In addition, miR-21 silencing has demonstrated effective results both in vitro and in vivo (24–28).”

    From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [24]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Akao Y.; Nakagawa Y.; Hirata I.; Iio A.; Itoh T.; Kojima K.; Nakashima R.; Kitade Y.; Naoe T. Role of Anti-Oncomirs MiR-143 and -145 in Human Colorectal Tumors. Cancer Gene Ther. 2010, 17, 398– 408. 20094072
  2. Esquela-Kerscher A.; Slack F. J. Oncomirs—MicroRNAs with a Role in Cancer. Nat. Rev. Cancer 2006, 6, 259– 269. 16557279
  3. Kitade Y.; Akao Y. MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, MiR-143 and -145, Function as Anti-Oncomirs and the Application of Chemically Modified MiR-143 as an Anti-Cancer Drug. J. Pharmacol Sci. 2010, 114, 276– 280. 20953119
  4. Krutovskikh V. A.; Herceg Z. Oncogenic MicroRNAs (Oncomirs) as a New Class of Cancer Biomarkers. Bioessays 2010, 32, 894– 904. 21105295
  5. Reshmi G.; Pillai M. R. Beyond HPV: Oncomirs as New Players in Cervical Cancer. FEBS Lett. 2008, 582, 4113– 4116. 19032954
  6. Kota J.; Chivukula R. R.; O’Donnell K. A.; Wentzel E. A.; Montgomery C. L.; Hwang H. W.; Chang T. C.; Vivekanandan P.; Torbenson M.; Clark K. R.; et al. Therapeutic MicroRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. Cell 2009, 137, 1005– 1017. 19524505 PMC2722880
  7. Liu C.; Kelnar K.; Liu B.; Chen X.; Calhoun-Davis T.; Li H.; Patrawala L.; Yan H.; Jeter C.; Honorio S.; et al. The MicroRNA MiR-34a Inhibits Prostate Cancer Stem Cells and Metastasis by Directly Repressing CD44. Nat. Med. 2011, 17, 211– 215. 21240262 PMC3076220
  8. Ross J. S.; Carlson J. A.; Brock G. Mirna: The New Gene Silencer. Am. J. Clin Pathol 2007, 128, 830– 836. 17951207
  9. De Palma M.; Naldini L. Antagonizing Metastasis. Nat. Biotechnol. 2010, 28, 331– 332. 20379176
  10. Ma L.; Reinhardt F.; Pan E.; Soutschek J.; Bhat B.; Marcusson E. G.; Teruya-Feldstein J.; Bell G. W.; Weinberg R. A. Therapeutic Silencing of MiR-10b Inhibits Metastasis in a Mouse Mammary Tumor Model. Nat. Biotechnol. 2010, 28, 341– 347. 20351690 PMC2852471
  11. Asangani I. A.; Rasheed S. A.; Nikolova D. A.; Leupold J. H.; Colburn N. H.; Post S.; Allgayer H. MicroRNA-21 (MiR-21) Post-Transcriptionally Downregulates Tumor Suppressor Pdcd4 and Stimulates Invasion, Intravasation and Metastasis in Colorectal Cancer. Oncogene 2008, 27, 2128– 2136. 17968323
  12. Chan J. A.; Krichevsky A. M.; Kosik K. S. MicroRNA-21 is an Antiapoptotic Factor in Human Glioblastoma Cells. Cancer Res. 2005, 65, 6029– 6033. 16024602
  13. Cheng A. M.; Byrom M. W.; Shelton J.; Ford L. P. Antisense Inhibition of Human MiRNAs and Indications for an Involvement of MiRNA in Cell Growth and Apoptosis. Nucleic Acids Res. 2005, 33, 1290– 1297. 15741182 PMC552951
  14. Loffler D.; Brocke-Heidrich K.; Pfeifer G.; Stocsits C.; Hackermuller J.; Kretzschmar A. K.; Burger R.; Gramatzki M.; Blumert C.; Bauer K.; et al. Interleukin-6 Dependent Survival of Multiple Myeloma Cells Involves the Stat3-Mediated Induction of MicroRNA-21 through a Highly Conserved Enhancer. Blood 2007, 110, 1330– 1333. 17496199
  15. Zhang Z.; Li Z.; Gao C.; Chen P.; Chen J.; Liu W.; Xiao S.; Lu H. MiR-21 Plays a Pivotal Role in Gastric Cancer Pathogenesis and Progression. Lab. Invest. 2008, 88, 1358– 1366. 18794849
  16. Zhu S.; Wu H.; Wu F.; Nie D.; Sheng S.; Mo Y. Y. MicroRNA-21 Targets Tumor Suppressor Genes in Invasion and Metastasis. Cell Res. 2008, 18, 350– 359. 18270520
  17. Su J.; Baigude H.; McCarroll J.; Rana T. M. Silencing MicroRNA by Interfering Nanoparticles in Mice. Nucleic Acids Res. 2011, 39, e38. 21212128 PMC3064800
  18. Huang X.; Schwind S.; Yu B.; Santhanam R.; Wang H.; Hoellerbauer P.; Mims A.; Klisovic R.; Walker A. R.; Chan K. K.; et al. Targeted Delivery of MicroRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clin. Cancer Res. 2013, 19, 2355– 2367. 23493348 PMC3644023
  19. Ashley C. E.; Carnes E. C.; Phillips G. K.; Padilla D.; Durfee P. N.; Brown P. A.; Hanna T. N.; Liu J. W.; Phillips B.; Carter M. B.; et al. The Targeted Delivery of Multicomponent Cargos to Cancer Cells by Nanoporous Particle-Supported Lipid Bilayers. Nat. Mater. 2011, 10, 389– 397. 21499315 PMC3287066
  20. Devulapally R.; Paulmurugan R. Polymer Nanoparticles for Drug and Small Silencing RNA Delivery to Treat Cancers of Different Phenotypes. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2014, 6, 40– 60. 23996830 PMC3865230
  21. Abeylath S. C.; Ganta S.; Iyer A. K.; Amiji M. Combinatorial-Designed Multifunctional Polymeric Nanosystems for Tumor-Targeted Therapeutic Delivery. Acc. Chem. Res. 2011, 44, 1009– 1017. 21761902
  22. Fattal E.; Barratt G. Nanotechnologies and Controlled Release Systems for the Delivery of Antisense Oligonucleotides and Small Interfering RNA. Br. J. Pharmacol. 2009, 157, 179– 194. 19366348 PMC2697810
  23. Babar I. A.; Cheng C. J.; Booth C. J.; Liang X.; Weidhaas J. B.; Saltzman W. M.; Slack F. J. Nanoparticle-Based Therapy in an In Vivo MicroRNA-155 (miR-155)-Dependent Mouse Model of Lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, E1695– E1704. 22685206 PMC3387084
  24. Ren Y.; Kang C. S.; Yuan X. B.; Zhou X.; Xu P.; Han L.; Wang G. X.; Jia Z.; Zhong Y.; Yu S.; et al. Co-Delivery of As-miR-21 and 5-FU by Poly(amidoamine) Dendrimer Attenuates Human Glioma Cell Growth In Vitro. J. Biomater. Sci., Polym. Ed. 2010, 21, 303– 314. 20178687
  25. Wu Y.; Crawford M.; Mao Y.; Lee R. J.; Davis I. C.; Elton T. S.; Lee L. J.; Nana-Sinkam S. P. Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol. Ther.—Nucleic Acids 2013, 2, e84. 23591808 PMC3650246
  26. Jin H.; Yu Y.; Chrisler W. B.; Xiong Y.; Hu D.; Lei C. Delivery of MicroRNA-10b with Polylysine Nanoparticles for Inhibition of Breast Cancer Cell Wound Healing. Breast Cancer 2012, 6, 9– 19. 22259248 PMC3256732
  27. Pecot C. V.; Calin G. A.; Coleman R. L.; Lopez-Berestein G.; Sood A. K. RNA Interference in the Clinic: Challenges and Future Directions. Nat. Rev. Cancer 2011, 11, 59– 67. 21160526 PMC3199132
  28. Fernandez-Fernandez A.; Manchanda R.; McGoron A. J. Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. Appl. Biochem. Biotechnol. 2011, 165, 1628– 1651. 21947761 PMC3239222
  29. Lu J. M.; Wang X.; Marin-Muller C.; Wang H.; Lin P. H.; Yao Q.; Chen C. Current Advances in Research and Clinical Applications of PLGA-Based Nanotechnology. Expert Rev. Mol. Diagn. 2009, 9, 325– 341. 19435455 PMC2701163
  30. Mundargi R. C.; Babu V. R.; Rangaswamy V.; Patel P.; Aminabhavi T. M. Nano/Micro Technologies for Delivering Macromolecular Therapeutics Using Poly(d,l-Lactide-Co-Glycolide) and Its Derivatives. J. Controlled Release 2008, 125, 193– 209. 18083265
  31. Harris J. M.; Chess R. B. Effect of Pegylation on Pharmaceuticals. Nat. Rev. Drug Discovery 2003, 2, 214– 221. 12612647
  32. Schmidts T.; Dobler D.; Nissing C.; Runkel F. Influence of Hydrophilic Surfactants on the Properties of Multiple W/O/W Emulsions. J. Colloid Interface Sci. 2009, 338, 184– 192. 19595359
  33. Woodrow K. A.; Cu Y.; Booth C. J.; Saucier-Sawyer J. K.; Wood M. J.; Saltzman W. M. Intravaginal Gene Silencing Using Biodegradable Polymer Nanoparticles Densely Loaded with Small-Interfering RNA. Nat. Mater. 2009, 8, 526– 533. 19404239 PMC2693358
  34. Paulmurugan R.; Sekar N. M.; Sekar T. V. Biodegradable Polymer Nanocarriers for Therapeutic Antisense MicroRNA Delivery in Living Animals. Proc. SPIE 2012, 8232, 823208. Colloidal Nanocrystals for Biomedical Applications VII.
  35. Cao M.; Deng X.; Su S.; Zhang F.; Xiao X.; Hu Q.; Fu Y.; Yang B. B.; Wu Y.; Sheng W.; et al. Protamine Sulfate-Nanodiamond Hybrid Nanoparticles as a Vector for MiR-203 Restoration in Esophageal Carcinoma Cells. Nanoscale 2013, 5, 12120– 12125. 24154605
  36. Mitchell P. S.; Parkin R. K.; Kroh E. M.; Fritz B. R.; Wyman S. K.; Pogosova-Agadjanyan E. L.; Peterson A.; Noteboom J.; O’Briant K. C.; Allen A.; et al. Circulating MicroRNAs as Stable Blood-Based Markers for Cancer Detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 10513– 10518. 18663219 PMC2492472
  37. Ma L. Role of MiR-10b in Breast Cancer Metastasis. Breast Cancer Res. 2010, 12, 210. 21067538 PMC3096969
  38. Sekar T. V.; Mohanram R. K.; Foygel K.; Paulmurugan R. Therapeutic Evaluation of MicroRNAs by Molecular Imaging. Theranostics 2013, 3, 964– 985. 24396507 PMC3881098
  39. Cheng C. J.; Saltzman W. M. Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing. Mol. Pharmaceutics 2012, 9, 1481– 1488. PMC3366258 22482958
  40. Iyevleva A. G.; Kuligina E.; Mitiushkina N. V.; Togo A. V.; Miki Y.; Imyanitov E. N. High Level of MiR-21, MiR-10b, and MiR-31 Expression in Bilateral vs. Unilateral Breast Carcinomas. Breast Cancer Res. Treat. 2012, 131, 1049– 59. 22057972
  41. Yan L. X.; Wu Q. N.; Zhang Y.; Li Y. Y.; Liao D. Z.; Hou J. H.; Fu J.; Zeng M. S.; Yun J. P.; Wu Q. L.; et al. Knockdown of MiR-21 in Human Breast Cancer Cell Lines Inhibits Proliferation, In Vitro Migration and In Vivo Tumor Growth. Breast Cancer Res. 2011, 13, R2. 21219636 PMC3109565
  42. Gu F.; Langer R.; Farokhzad O. Formulation/Preparation of Functionalized Nanoparticles for In Vivo Targeted Drug Delivery. In Micro and Nano Technologies in Bioanalysis; Foote R. S., Lee J. W., Eds.; Humana Press: New York, 2009; Vol. 544, pp 589– 598. PMC4059054 19488725

Cited by

Sorted by citations

Authors
Devulapally, R., Sekar, N. M., Sekar, T. V., Foygel, K., Massoud, T. F., Willmann, J. K., & Paulmurugan, R.
Affiliations
  • Stanford Medicine (US)
  • Stanford University School of Medicine, Stanford University , , 3155 Porter Drive , , ,
Corresponding author
Paulmurugan, Ramasamy
ORCID
Venue
ACS Nano
Publisher
American Chemical Society (ACS)
Published
2015-02-04
Volume
9
Issue
3
Pages
2290-2302
ISSN
  • 1936-0851 (ISSN-L)
  • 1936-086X
DOI
10.1021/nn507465d
PMC
PMC4374409
OpenAlex
W2050732886
Cited by
260
References
4
Citations by year
2026: 13 · 2025: 14 · 2024: 11 · 2023: 23 · 2022: 32 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 27 · 2017: 18 · 2016: 23 · 2015: 10
FWCI
11.30
Type
journal article
Language
en
Open access
Licence
Locations
  • ACS Nano (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01 CA161091)
  • Canary Center, Stanford University (NA)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
triple-negative breast cancer, miR-21, miR-10b, polymeric nanoparticles, co-delivery, metastasis, apoptosis, tumor xenografts, molecular imaging, nanoparticle drug delivery
MeSH terms
Animals, Biological Transport, Cell Survival, Cell Transformation, Neoplastic, Drug Carriers, Female, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Polyethylene Glycols, Polyglactin 910, Genetic Therapy, RNA Stability, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Nanomedicine, Mice, Receptors, Urokinase Plasminogen Activator, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review